Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
disopyramide
- Development stage
- Approved
- Lead developer
- Pfizer
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
Disopyramide is a class 1A antiarrhythmic agent used to treat life-threatening ventricular arrhythmias, such as sustained ventricular tachycardia. It works by inhibiting fast sodium channels in cardiac myocytes, thereby decreasing the rate of diastolic depolarization (phase 4), reducing the upstroke velocity (phase 0), and increasing the action potential duration in normal cardiac cells. This results in increased resistance of the heart to abnormal electrical activity and helps restore normal rhythm. Disopyramide also has anticholinergic and local anesthetic properties but does not block alpha- or beta-adrenergic receptors[1][3][5][6]. Its primary indication is for documented ventricular arrhythmias that are potentially life-threatening.
- Brand names
- NorpaceNorpace CRRythmodan
- Other names
- disopyramide
02
Targets
SCN5A (Sodium channel protein type 5 subunit alpha)
Beyond the preview
Go deeper on disopyramide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on disopyramide.